Furthermore, to verify the influence of IFITM4P on anti-PD-1 therapy, we utilized PD-1 mAb to treat mouse early tongue leukoplakia induced with 4NQO + LPS or 4NQO alone (Figure 4L). The gene discussed is IFITM4P; the disease is leukoplakia of tongue.